The contract bioanalytical testing services company BioAgilytix is expanding its technology suite with the addition of Sword Bio’s detection platform for immunoassays.
Evotec is integrating Sanofi’s infectious disease unit into its organization and will collaborate to launch new "open innovation" initiatives aimed at accelerating infectious disease research.
Medidata is acquiring Shyft Analytics for $195m, creating a new platform that will combine clinical development with commercial and real-world data analytics in a first for the industry, says a company executive.
Wasdell Group is investing £500k ($669k) in a new laboratory as the first phase of an expansion strategy, which includes a similar investment in Ireland "to cater for all situations after Brexit," says managing director.
Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.
SIGA is slated to receive FDA approval for the world’s first antiviral drug to treat smallpox – a milestone not reached in isolation, but in collaboration with several CROs, government agencies, and others.
The preclinical contract research organization (CRO) Admescope has acquired MetaSafe in a deal which will bolster its drug metabolism services for clinical phase projects.
Celltrion has launched Bio CDMO, its new contract development and manufacturing business and part of the company's "open innovation strategy" to expand its drug pipeline portfolio.
Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.
The Northern Ireland development agency Invest NI has awarded Fusion Antibodies a grant worth up to £213,000 ($283,231), which will help the CRO double its capacity and employee count.
Lonza has added to its hepatocytes portfolio to provide researchers with the foundation to create “more physiologically relevant” in vitro models for liver disease research.
Bayer AG and Elsevier studied more than 1.6m adverse events to show how big data can be used to reduce animal testing and design trials "altered to potential risks," says researcher.
The UK-based biopharmaceutical company PhoreMost has completed a £11m ($15m) Series-A investment round, preparing the company for “more collaborations” later this year, says CEO.
